BACKGROUND: Dyslipidaemia may account for increased risk of @entity65 in @entity1144 . Pharmacotherapy is often indicated in these @entity1 , but the optimal approach remains unclear. We investigated the effects of @entity2993 and fish oil on plasma lipid and lipoprotein levels, including remnant-like particle- @entity165 and apolipoprotein C-III, in dyslipidaemic @entity1 with @entity1144 . METHODS: We carried out a 6-week randomized, placebo-controlled, 2 x 2 factorial intervention study of @entity2993 (40 mg day(-1)) and fish oil (4 g day(-1)) on plasma lipids and lipoproteins in 52 @entity28 @entity1 (age 53 +/- 1 years, BMI 33.7 +/- 0.55 kg m(-2)) with dyslipidaemia and insulin resistance. Treatment effects were analysed by general linear modelling. RESULTS: @entity2993 had significant main effects in decreasing @entity1674 (-0.38 +/- 0.02 mmol L(-1), P = 0.002), total @entity165 (-1.89 +/- 0.17 mmol L(-1), P = 0.001), LDL- @entity165 (-1.78 +/- 0.14 mmol L(-1), P = 0.001), remnant-like particle- @entity165 (-0.08 +/- 0.04 mmol L(-1), P = 0.035), @entity755 (-49 +/- 4 mg dL(-1), P = 0.001), apolipoprotein C-III (-12.6 +/- 6.1 mg L(-1), P = 0.044) and in increasing HDL- @entity165 (+0.10 +/0- 0.04 mmol L(-1), P = 0.007). Fish oil had significant main effects in decreasing @entity1674 (-0.38 +/- 0.11 mmol L(-1), P = 0.002) and in increasing HDL- @entity165 (+0.07 +/- 0.04 mmol L(-1), P = 0.041). There were no significant changes in weight or insulin resistance during the study. CONCLUSIONS: @entity2993 and fish oil have independent and additive effects in correcting dyslipidaemia in @entity1144 @entity1 . Improvement in @entity66 may occur only with use of @entity2993 . Combination treatment with @entity1780 and fish oil may, however, offer an optimal therapeutic approach for globally correcting dyslipidaemia in @entity28 .

Factorial study of the effects of XXXX and fish oil on dyslipidaemia in @entity1144 .

@entity1 :: ('9606', 'Species') :: ['patients', 'men'] @entity66 :: ('MESH:D004194', 'Disease') :: ['abnormalities in remnant lipoproteins'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity', 'obese'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity2993 :: ('MESH:C065179', 'Chemical') :: ['atorvastatin', 'Atorvastatin'] @entity755 :: ('338', 'Gene') :: ['apolipoprotein B'] @entity1780 :: ('CHEBI:35664', 'Chemical') :: ['statin'] @entity1144 :: ('MESH:D056128', 'Disease') :: ['viscerally obese', 'central obesity', 'visceral obesity'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity2993 :: (MESH:C065179,Chemical) :: ['atorvastatin']
